Quick Answer
Keros Therapeutics, Inc. reported Cash and Equivalents of $287.42 million for fiscal year 2025.
Keros Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $287.42M | -48.7% |
| 2024 | $559.93M | +69.1% |
| 2023 | $331.15M | +18.7% |
| 2022 | $279.05M | +21.3% |
| 2021 | $230.04M | -13.5% |
| 2020 | $265.88M | +3687.4% |
| 2019 | $7.02M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $693.47M | +30.7% | +0.5% |
| June 30, 2025 | $690.22M | +70.1% | -4.2% |
| March 31, 2025 | $720.54M | +62.9% | +28.7% |
| December 31, 2024 | $559.93M | +69.1% | +5.5% |
| September 30, 2024 | $530.68M | +84.3% | +30.8% |
| June 30, 2024 | $405.86M | +26.0% | -8.3% |
| March 31, 2024 | $442.44M | +25.9% | +33.6% |
| December 31, 2023 | $331.15M | +18.7% | +15.0% |
- Keros Therapeutics, Inc. showed a decrease of -48.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Keros Therapeutics, Inc.’s cash and equivalents has grown by 3994.2% (from $7.02 million to $287.42 million).
- The most recent figure is from Keros Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: